Abstract: The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Abstract: The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Abstract: The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Abstract: The present disclosure provides methods of treatment using ophthalmic compositions, comprising 1-perfluorohexyloctane, which are useful in the treatment of ocular surface damage of the cornea and/or symptoms of dryness.

Abstract: The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.

Abstract: This specification discloses methods for processing starch by applying a hot aqueous fluid to the starch in an amount up to about 45% (wt. % of the starch). Depending on the among of fluid the processes may be used to agglomerate the starch or to precook or pregelatinize the starch. The method is useful applied to native and modified starches and particularly useful for pregelatinizing or agglomerated thermally inhibited starch having a moisture content less than about 2% (wt. % of the starch).

Abstract: The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Abstract: The present disclosure is in the field of ointments which can be useful for the treatment of diseases or conditions associated with lipid barrier damage of the skin. The ointment comprises a semifluorinated alkane and a solid thickening agent, e.g., a wax, a triglyceride, cetyl alcohol, cetyl palmitate, or tetradecanol.

Abstract: The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Abstract: The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.

Abstract: The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Abstract: The present invention relates to a method of removing an RNA fraction with ?200 nucleotides in length from a whole blood sample. The present invention also relates to a method of purifying an RNA fraction with <200 nucleotides in length from a whole blood sample. The present invention further relates to a method of determining the level of RNA molecules with <200 nucleotides in length. In addition, the present invention relates to a method for diagnosing a disease in an individual. Moreover, the present invention relates to a kit which is useful for carrying out the methods of the present invention.

Abstract: The present disclosure relates to topical sunscreen formulations comprising a semifluorinated alkane and a metal oxide selected from titanium dioxide, zinc oxide or mixtures thereof.

Abstract: The invention provides ophthalmic composition comprising cyclosporine and a semifluorinated alkane for use in the treatment of ocular allergy and any symptoms associated thereto.

Abstract: A pharmaceutical composition comprising a semifluorinated alkane of formula (I): F(CF2)n(CH2)mH, wherein n is an integer from 4 to 6, and m is an integer from 5 to 8, for use in the treatment or prevention of a disease or condition relating to an ocular surface of an eye of an individual, wherein the individual is a contact lens wearer, and wherein the contact lens is a hydro gel contact lens and the composition is administered topically to a surface of the eye of the individual before the contact lens is inserted to the eye of the individual and/or during contact lens wear and/or after the contact lens has been removed from the eye of the individual, or wherein the contact lens is a silicone hydrogel contact lens and the composition is administered topically to a surface of the eye of the individual after the contact lens has been removed from the eye of the individual.

Abstract: The present disclosure is in the field of ointments which can be useful for the treatment of diseases or conditions associated with lipid barrier damage of the skin. The ointment comprises a semifluorinated alkane and a solid thickening agent, e.g., a wax, a triglyceride, cetyl alcohol, cetyl palmitate, or tetradecanol.

Abstract: The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.

Abstract: The present disclosure provides methods of treatment using ophthalmic compositions, comprising 1-perfluorohexyloctane, which are useful in the treatment of ocular surface damage of the cornea and/or symptoms of dryness.

Abstract: The present disclosure relates to topical sunscreen formulations comprising a semifluorinated alkane and a metal oxide selected from titanium dioxide, zinc oxide or mixtures thereof.

Abstract: The present invention relates to methods, kits and means for diagnosing Parkinson's disease in a blood sample from a subject. Further, the present invention relates to a set of polynucleotides for detecting sets of miRNAs for diagnosing Parkinson's disease in a blood sample from a subject.